Figure 2.
Visual summary of the natural history of HCC that focus on key differences and challenges when designing studies to evaluate risk stratification vs early detection biomarkers. For risk stratification biomarkers, it is crucial to ensure that the patients are free of HCC. This includes a 2-year period to minimize the risk of undetectable microscopic HCC, which is a potential confounder in these studies. Used with permission from ©Mount Sinai Health System.